Key result
Eptifibatide consistently reduced death or myocardial infarction across regions after adjustment, with relative reductions ranging from 17-42% in Western Europe to 23-35% in North America.
Why the study?
Does eptifibatide reduce the 30-day composite of death or myocardial infarction in patients with acute coronary syndromes without persistent ST-elevation across different geographic regions?
RCT (n=9,461)
Randomized
Yes
Does eptifibatide reduce the 30-day composite of death or myocardial infarction in patients with acute coronary syndromes without persistent ST-elevation across different geographic regions?
No takes yet. Share an insight, caveat, or question.
Supports eptifibatide in non-ST-elevation ACS irrespective of region; confirms consistent benefit in multinational RCTs.
K. Martijn Akkerhuis (2000) conducted an RCT in Acute coronary syndromes without persistent ST-elevation (n=9,461). Eptifibatide vs. Placebo was evaluated on 30-day composite of death or myocardial infarction. Eptifibatide consistently reduced death or myocardial infarction across regions after adjustment, with relative reductions ranging from 17-42% in Western Europe to 23-35% in North America.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: